Abstract
Many clinical studies have documented the efficacy of amantadine and rimantadine for prophylaxis and treatment of influenza A virus infections (Douglas 1990; Tominack and Hayden 1987). Antiviral activity has been demonstrated in various animal models of influenza (Hayden 1986) and during clinical use in humans (Douglas 1990). Amantadine- and rimantadine-resistant mutants have been recovered during studies in mice (Oxford et al. 1970, Oxford and Potter 1972), birds (Webster et al. 1985; Beard et al. 1987; Bean et al. 1989), and recently in children and adults treated with these drugs (Hall et al. 1987; Thompson et al. 1987; Belshe et al. 1988; Hayden et al. 1989). The impact of drug resistance on the clinical usefulness of these drugs is thus of obvious concern. Factors which may influence the clinical importance of drug-resistant viruses include their frequency and rapidity of emergence, genetic stability, transmissibility, pathogenicity, and ability to compete epidemiologically with wild-type viruses (Bean et al. 1989). The following sections review the limited information available from animal and human studies that address these characteristics and the correlation of these factors with particular resistance mutations.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Appleyard G (1977) Amantadine-resistance as a genetic marker for influenza viruses. J Gen Virol 36: 249–255
Bean WJ, Threlkeld SC, Webster RG (1989) Biologic potential of amantadine-resistant influenza A virus in an avian model. J Infect Dis 159: 1050–1056
Beard CW, Brugh M, Webster RG (1987) Emergence of amantadine-resistant H5N2 avian influenza virus during a simulated layer flock treatment program. Avian Dis 31: 533–537
Belshe RB, Hay AJ (1989) Drug resistance and mechanisms of action on influenza A viruses. J Respir Dis 10: S52 - S61
Belshe RB, Smith MH, Hall CB, Betts R, Hay AJ (1988) Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J Virol 62: 1508–1512
Belshe RB, Burk B, Newman F, Cerruti RL, Sim IS (1989) Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J Infect Dis 159: 430–435
Bricaire AF, Hannoun C, Boissel JP (1990) Prévention de la gripple A. Efficacité et tolérance du chlorhydrate de rimantadine. Presse Med 19: 69–72
Couch RB, Kasel JA, Glezen WP, Cate TR, Six HR, Taber LH, Frank AL, Greenberg SB, JM Zahradnik, Keitel WA (1986) Influenza: its control in persons and populations. J Infect Dis 153: 431–440
Douglas RG (1990) Prophylaxis and treatment of influenza. N Engl J Med 322: 443–450
Galbraith AW, Oxford JS, Schild GC, Watson GI (1969a) Protective effect of 1-adamantanamine hydrochloride on influenza A2 infections in the family environment. A controlled double-blind study. Lancet 2: 1026–1028
Galbraith AW, Oxford JS, Schild GC, Watson GI (1969b) Study of 1-adamantanamine hydrochloride used prophylactically during the Hong Kong influenza epidemic in the family environment. Bull WHO 41: 677–682
Hall CB, Dolin R, Gala CL, Markovitz DM, Zhang YO, Madore PH, Disney FA, Talpey WB, Green JL, Francis AB, Pichichero ME (1987) Children with influenza A infection: treatment with rimantadine. Pediatrics 80: 275–282
Hay AJ (1989) The mechanism of action of amantadine and rimantadine against influenza viruses. In: Notkins AL, Oldstone MBA (eds) Concepts in viral pathogenesis Ill. Springer, Berlin Heidelberg New York, pp 561–567
Hay AJ, Kennedy NTC, Skehel JJ, Appleyard G (1979) The matrix protein gene determines amantadine-sensitivity of influenza viruses. J Gen Virol 44: 807
Hay AJ, Zambon HC, Wolstein Holme AJ, Skehel JJ, Smith MH (1986) Molecular basis of resistance of influenza A viruses to amantadine. J Antimicrob Chemother [Suppl B] 18: 19–29
Hay AJ, Grambas S, Bennett MS (1991) Resistance of influenza A viruses to amantadine and rimantadine. In: Kumar A (ed) Advances in molecular biology and targeted treatment for AIDS. Plenum, New York (.n press)
Hayden FG, Cote KM, Douglas RG Jr (1980) Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob Agents Chemother 17: 865–870
Hayden FG (1986) Animal models of influenza virus infection for evaluation of antiviral agents. In: Zak O, Sande MA (eds) Experimental models in antimicrobial chemotherapy, Academic, Orlando, pp 353–371
Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W (1989) Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 321: 1696–1702
Hayden F, Sperber SJ, Belshe R, Clover R, Hay A, Pyke S (1991) Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother 35: 1741–1747
Heider H, Adamczyk B, Presber HW, Schroeder C, Feldblum R, Indulen MK (1981) Occurrence of amantadine-and rimantadine-resistant influenza A virus strains during the 1980 epidemic. Acta Virol (Praha) 25: 395–400
Kendal A (1990) A prototype kit for amantadine sensitivity testing of influenza viruses (Abstract P 34–021). 8th International Congress of Virology, Berlin
Lubeck MD, Schulman JL, Palese P (1978) Susceptibility of influenza A viruses to amantadine is influenced by the gene coding for M protein. J Virol 28: 710–716
Mast EE, Davis, JP, Harmon MW, Arden NH, Circo R, Tyszka GE (1989) Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2) (Abstr 65). In: 29th lnterscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, p 111
Oxford JS, Potter CW (1973) Aminodamantane-resistant strains of influenza A2 virus. J Hyg (Camb) 71: 227–236
Oxford JS, Logan IS, Potter CW (1970) Passage of influenza strains in the presence of aminoadamantane. Ann NY Acad Sci 173: 300–313
Pemberton RM, Jennings R, Potter CW, Oxford JS (1986) Amantadine resistance in clinical influenza A (H3N2) and (H1 N1) virus isolates. J Antimicrob Chemother [Suppl] 18: 135–140
Roumillat F, Rocha E, Regnery H, Wells D, Cox N (1990) Emergence of amantadine-resistant influenza A viruses in nursing homes during the 1989–1990 influenza season (Abstr P34–42). 8th International Congress of Virology, Berlin
Sugrue RJ, Hay AJ (1991) Structural characteristics of the M2 protein of influenza A viruses: evidence that it forms a tetrameric channel. Virology 180: 617–624
Sugrue RJ, Bahadur G, Zambon MC, Hall-Smith M, Douglas AR, Hay AJ (1990) Specific structural alteration of the influenza haemagglutinin by amantadine. EMBO J 9: 3469–3476
Sweet C, Hayden FG, Jakeman KJ, Grambas S, Hay AJ (1991) Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. J Infect Dis 164: 969–972
Thompson J, Fleet W, Lawrence E, Pierce E, Morris L, Wright P (1987) A comparison of acetaminophen and rimantadine in the treatment of influenza A infection in children. J Med Virol 21: 249–255
Tominack RL, Hayden FG (1987) Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. In: Knight V, Gilbert B (eds) Infectious disease clinics of North America. Saunders, Philadelphia, pp 459–478
Webster RG, Kawaoka Y, Bean WJ, Beard CW, Brugh M (1985) Chemotherapy and vaccination: a possible strategy for the control of highly virulent influenza virus. J Virol 55: 173–176
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Hayden, F.G., Hay, A.J. (1992). Emergence and Transmission of Influenza A Viruses Resistant to Amantadine and Rimantadine. In: Holland, J.J. (eds) Genetic Diversity of RNA Viruses. Current Topics in Microbiology and Immunology, vol 176. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77011-1_8
Download citation
DOI: https://doi.org/10.1007/978-3-642-77011-1_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-77013-5
Online ISBN: 978-3-642-77011-1
eBook Packages: Springer Book Archive